Odyssey Health, Inc.

Odyssey Health, Inc. is a Nevada-based medical product development company focused on acquiring, licensing, and advancing healthcare technologies through its operating subsidiaries. Its reported pipeline includes the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device, with development and commercialization intended to occur through third-party partners and distributors.

0.01

— Odyssey Health, Inc.
	%
CardioMap device	40% Heart monitoring and screening technology under development for medical use.
Save-A-Life device	40% Choking rescue device designed for emergency response and airway obstruction use.
Licensing and distribution rights	15% Potential license fees, royalties, and distribution agreements for approved products.
Medical technology acquisition	5% Acquisition of medical products, assets, and intellectual property for development.

Odyssey Health’s end customers are expected to be healthcare providers, distributors, and commercial partners that...

Healthcare providersprimary
Hospitals, clinics, and care settings that would buy or use approved monitoring and rescue devices.
Medical device distributorsprimary
Third-party distributors that sell the company’s products and provide market access.
Licensing partnersprimary
Commercial partners that pay upfront fees and royalties to market or sublicense products.
Emergency-use end userssecondary
Users and institutions that need choking rescue tools for rapid response situations.

Odyssey Health is headquartered in Las Vegas, Nevada, and is organized as a U.S. public company with subsidiaries in...

•Headquartered in Las Vegas, Nevada
•U.S. corporate base and primary regulatory home market
•Australia subsidiary supports international structure
•Planned commercialization in the United States and abroad
•International licensing is part of the growth model

The company’s strategy is to acquire or develop medical technologies, secure regulatory clearance, and then...

Obtain regulatory clearance for product candidatesshort-term

Commercial sales depend on FDA or other regulatory approval.

Build distribution and licensing partnershipsshort-term

Third-party channels are intended to accelerate market entry and revenue generation.

Broaden the technology platformmedium-term

Additional uses can increase the commercial value of the core technology base.

Odyssey Health faces the typical risks of an early-stage medical device developer, including regulatory approval risk,...

critical

Regulatory approval risk

Product candidates cannot be sold commercially until cleared or approved by regulators.

Scope: CardioMap and Save-A-Life
Materiality: high

high

Distribution network risk

The company expects third parties to market and sell products, which may not materialize or perform well.

Scope: U.S. and international channel partners
Materiality: high

high

Funding and going-concern risk

Development-stage operations require external capital before product revenue exists.

Scope: Corporate liquidity and development spending
Materiality: high

high

Intellectual property risk

The business depends on patents, trademarks, and proprietary technology to protect value.

Scope: Medical device technologies and acquired IP
Materiality: medium

Going concern assessment

Affects investor assessment of solvency and capital needs

Stock-based compensation

Affects operating loss and dilution analysis

Debt and interest expense

Affects net loss and cash flow interpretation

Intangible asset valuation and impairment

Could materially affect balance sheet and earnings

Odyssey Health, Inc.

Regulatory approval risk

Distribution network risk

Funding and going-concern risk

Intellectual property risk

Adagio Medical Holdings, Inc.

ODYSSEY MARINE EXPLORATION INC

Cardio Diagnostics Holdings, Inc.

Edgewise Therapeutics, Inc.

HeartBeam, Inc.

Corvex, Inc.